6185 — Cansino Biologics Share News
0.000.00%
Last trade - 00:00- HK$5.73bn
- HK$4.18bn
- CNY1.06bn
Brief: CanSino Biologics Inc Sees FY Net Loss Attributable RMB335.0 Mln To RMB385.0 Mln
Brief: Cansino Biologics Says Menhycia Obtained Drug Registration Certificate In Indonesia
Brief: CanSino Biologics Inc Says Acceptance Of New Drug Application By NMPA
Brief: CanSino Biologics Says Supplemental Drug Application For Menhycia Accepted By NMPA China
Brief: Cansino Biologics Says 9M Operating Revenue RMB567.1 Million
Brief: Cansino Biologics's Net Loss Narrows In H1
Indonesia ramps up fight against tuberculosis amid concerns on economic impact
Brief: CanSino Says Q1 Net Loss At 170.1 Million Yuan
Brief: Cansino Biologics' 2023 Net Loss At 1.5 Bln Yuan
Brief: CanSino Sued By Belcher Farmaceutica Over COVID Vaccine Cooperation Dispute
Brief: CanSino's Prelim 2023 Net Loss 1.4 Bln Yuan
Brief: CanSino Sees 2023 Net Loss Of 1.3-1.5 Bln Yuan
Scientists see risk of lost opportunity for long COVID research in China
Brief: CanSino's COVID Vaccine Gets Approval For Emergency Use
Brief: Cansino Biologics Says Q3 Net Loss Of 143.6 Mln Yuan
China's CanSino seeks more vaccine contracts after AstraZenca deal
Brief: CanSino Biologics' Unit To Invest In Solution Group Berhad
Brief: CanSino Biologics' COVID Vaccine Gets Certificate In Indonesia
Brief: CanSino's Employee Stock Ownership Platform Plans To Unload Up To 1.98% Co Stakes